Development Predicament and Countermeasures of Anti-tumor Bio-similar Industry in China

  • Yingjie Xie
DOI: https://doi.org/10.18686/aem.v9i4.180
Keywords: Biosimilar, Anti-tumor, Industry, Development, Countermeasure

Abstract

Biosimilar has the advantages of precise efficacy, high safety and stable quality, and occupy an important position in the field of anti-tumor therapy. In order to reduce the expenditure of drugs, the research and development of biosimilar drugs has attracted much attention. Compared with European and American countries in the development of the anti-tumor biosimilar industry, there are still some shortcomings and parts that need improvement in China. According to the current development status of China, analyzed the reasons for the development dilemma of my country’s anti-tumor biosimilar industry, and put forward suggestions for the development of this industry.

References

[1] Guo R. Development and clinical application of anti-tumor biosimilar drugs (in Chinese). Journal of Practical Oncology 2020; (4): 310–313.

[2] Li Y, Tian L. Research on biosimilar pharmacovigi-lance (in Chinese). 2013 Annual Meeting of the Pharmaceutical Affairs Management Professional Committee of the Chinese Pharmaceutical Associa-tion and the “Medicine Safety and Scientific De-velopment” Academic Forum (in Chinese); 2013.

[3] Blanco-García E, Ledón N, Lage-Dávila A. Rising cancer drug prices: What can low- and mid-dle-income countries do?. MEDICC Review 2018; 20(4): 35–39．

[4] Huo Y, Yang J. Discussion on the reasons for the cluster development of biopharmaceutical industry (in Chinese). Science & Technology Progress and Policy 2005; (1): 84–86.

[5] Xie X, Wu J. Study on status and countermeasures about biosimilars in China. China Biotechnology 2012; (3): 136–142.

[6] Meng X, Gao S, Shu C. Analysis of biopharmaceu-tical development and countermeasure research of China. China Soft Science 2014; (4): 14–24.

[7] Yang Y, Yang B. Thoughts on the pharmaceutical research of biosimilars (in Chinese). World Latest Medicine Information 2017; (A1): 85.
Published
2021-02-02
Issue
Vol 8 No 4 (2019)
Section
Original Research Article

Copyright (c) 2021 Yingjie Xie

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.